2024
Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial
Buga A, Harper D, Sapper T, Hyde P, Fell B, Dickerson R, Stoner J, Kackley M, Crabtree C, Decker D, Robinson B, Krystal G, Binzel K, Lustberg M, Volek J. Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial. PLOS ONE 2024, 19: e0296523. PMID: 38166036, PMCID: PMC10760925, DOI: 10.1371/journal.pone.0296523.Peer-Reviewed Original ResearchMeSH Keywords3-Hydroxybutyric AcidBreast NeoplasmsDiet, KetogenicFeasibility StudiesFemaleHumansInsulin ResistanceInsulinsKetosisConceptsMetastatic breast cancerStage IV metastatic breast cancerKetogenic dietInsulin resistanceNutritional ketosisPlasma insulinBreast cancerBody compositionAdjuvant therapeutic interventionsMetabolic outcomesCancer patientsPlasma glucoseMetabolic effectsBody fatShort-term studiesBody weightPleiotropic mechanismsTherapeutic interventionsConsistent bloodPhase IMonthsWomenCancerAd libitumChemotherapy
2020
Feasibility of implementing a text-based symptom-monitoring program of endometrial, ovarian, and breast cancer patients during treatment
Naughton MJ, Salani R, Peng J, Lustberg M, DeGraffinreid C, Moon J, Loyan H, Beverly Hery CM, Paskett ED. Feasibility of implementing a text-based symptom-monitoring program of endometrial, ovarian, and breast cancer patients during treatment. Quality Of Life Research 2020, 30: 3241-3254. PMID: 33052514, PMCID: PMC8528739, DOI: 10.1007/s11136-020-02660-w.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsFatigueFeasibility StudiesFemaleHumansMiddle AgedQuality of LifeSurveys and QuestionnairesConceptsBreast cancer patientsCancer patientsPatient Health QuestionnaireOverall mean ageHealth care teamNon-medical needsNon-Hispanic whitesLay navigatorsPatient navigationMean ageSleep disturbancesCare teamHealth QuestionnaireLow adherencePatient responseAverage adherenceSleep qualitySymptom monitoringBreast patientsPatientsCancer typesMonthly feedbackMonthsGlobal qualitySymptoms
2019
Partnered, adapted argentine tango dance for cancer survivors: A feasibility study and pilot study of efficacy
Worthen-Chaudhari L, Lamantia M, Monfort S, Mysiw W, Chaudhari A, Lustberg M. Partnered, adapted argentine tango dance for cancer survivors: A feasibility study and pilot study of efficacy. Clinical Biomechanics 2019, 70: 257-264. PMID: 31751861, DOI: 10.1016/j.clinbiomech.2019.08.010.Peer-Reviewed Original ResearchConceptsCancer survivorsPostural controlCOP measuresMean satisfaction rateNeurotoxic cancer treatmentsBalance training programPostural control deficitsTango danceHalf of participantsPreliminary efficacySensorimotor trainingNormal rangePromising treatmentPressure measuresQuiet standingSatisfaction rateBalance deficitsCancer treatmentPilot studySurvivorsMore sessionsFeasibility criteriaTango classesControl deficitsMore studies
2016
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair
Villalona-Calero M, Duan W, Zhao W, Shilo K, Schaaf L, Thurmond J, Westman J, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. Journal Of The National Cancer Institute 2016, 108: djv437. PMID: 26848151, PMCID: PMC4948564, DOI: 10.1093/jnci/djv437.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesDiarrheaDrug Administration ScheduleFanconi AnemiaFatigueFeasibility StudiesFemaleGenes, BRCA1Genes, BRCA2Germ-Line MutationHumansMaleMiddle AgedMitomycinNeoplasmsPedigreePoly(ADP-ribose) Polymerase InhibitorsRecombinational DNA RepairThrombocytopeniaConceptsPatient tumorsPARP inhibitorsFunctional deficiencySafety/feasibilityDose-escalation trialBRCA germline mutationsCancer patient tumorsClinical Laboratory Improvement AmendmentsArchival tumor materialCombination armEscalation trialAntitumor responseClinical benefitSevere toxicityTumor specimensPatientsDose levelsSolid tumorsGermline analysisGermline alterationsTumor materialTumorsVeliparibBRCA genesGermline mutations
2011
Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Berger M, Dunlea L, Rettig A, Lustberg M, Phillips G, Shapiro C. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care In Cancer 2011, 20: 1991-1997. PMID: 22089428, PMCID: PMC3411299, DOI: 10.1007/s00520-011-1303-9.Peer-Reviewed Original ResearchConceptsInfusion hypersensitivity reactionPaclitaxel-based chemotherapyHypersensitivity reactionsRescue medicationPaclitaxel dosesSecond doseDoses of paclitaxelBreast cancer patientsUse of paclitaxelPotential unwanted side effectsConclusionsIn patientsPrimary endpointSubsequent dosesUnwanted side effectsCancer patientsPremedicationSide effectsPatientsSolid tumorsDoses 3MedicationsChemotherapyDosesHypersensitivityDose